25.11.2013 13:51:52
|
Cubist Pharma: Ceftolozane/tazobactam Met Primary Endpoint In Phase 3 Trial
(RTTNews) - Cubist Pharmaceuticals, Inc. (CBST) Monday announced positive top-line results from the company's pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections or cUTI.
Ceftolozane/tazobactam met its primary endpoint of statistical non-inferiority compared to levofloxacin.
The primary endpoint is a composite of microbiological eradication and clinical cure rate at 5 - 9 days after end of therapy. The 95 percent confidence interval around the treatment difference had lower and upper bounds of 2.3 percent and 14.6 percent, respectively, favoring ceftolozane/tazobactam.
Results of the secondary analyses were consistent with and supportive of the primary outcome.
The spectrum of Gram-negative pathogens seen in the trial was typical of that seen in other clinical trials in patients with complicated urinary tract infections.
Cubist is concluding a pivotal Phase 3 trial of ceftolozane/tazobactam in patients with complicated intra-abdominal infections or cIAI.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Cubist Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |